In this episode, we're exploring the latest in radiotherapy, especially radioligand therapy for cancer treatment. Charles spotlights some promising trials coming up in 2024 that involve companies like Ymabs, Marianao Oncology, and many more fighting hard-to-treat cancers with new techniques and talks about big deals in the industry, like when Point Pharma and Ray's bio were bought. These deals show how important radiotherapy is in business and strategy.
Looking ahead, Charles sees a bright future for radiotherapy, with better supply chains possibly making treatments cheaper and more accessible.
Here's what you are in for:
00:00 Introduction to New Radiotherapy Methods
00:28 Understanding Radiotherapy Today
02:14 Early Trials in Radiotherapy
07:54 Key Trials and Their Effects on the Industry
12:17 The Future of Radiotherapy
13:21 Final Thoughts and What's Next
Watch full episodes on:
- Spotify: https://open.spotify.com/episode/3yxgyMQaJgeFQAzUaQP1Wj?si=f0482e64d0d745a4
- Apple: https://podcasts.apple.com/us/podcast/radiotherapy-2024-quick-look-into-the-radiotherapy/id1736051162?i=1000651795197
ABOUT CHARLES
Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.
He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of Early clinical stage SME biotechs on the East Coast and DACH.
Connect with Charles:
LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
Click here for more details.
